<DOC>
	<DOCNO>NCT03053167</DOCNO>
	<brief_summary>Irinotecan raltitrexed active advanced colorectal cancer ( ACC ) , act different mechanism , partially overlap toxicity profile . The purpose study evaluate efficacy safety irinotecan plus raltitrexed second-line treatment advance colorectal cancer patient .</brief_summary>
	<brief_title>Irinotecan Plus Raltitrexed Second-line Treatment Advanced Colorectal Cancer Patients</brief_title>
	<detailed_description>The standard initial treatment patient advance colorectal cancer ( ACC ) amenable surgical resection palliative 5-fluorouracil ( 5-FU ) -based chemotherapy . However , response rate low prognosis remain poor , median survival time one year . Until recently , second-line therapy option limit . Irinotecan semisynthetic camptothecin derivate act DNA-topoisomerase-1 inhibitor , frequent toxic effect diarrhea , neutropenia cholinergic syndrome . Raltitrexed quinazoline folate-based specific thymidylate synthase inhibitor , clinical activity set similar modulate 5-FU regimen well toxicity profile ( mainly asthenia increase serum transaminase level ) . There seem cross-resistance 5-FU raltitrexed . Irinotecan raltitrexed different toxicity profile modes action . Both drug active single agent may give short 3-weekly infusion , thus obviate complex schedule need implantable venous access device . Preclinical study demonstrate pronounced sequence-dependent synergy SN-38 ( active metabolite irinotecan ) raltitrexed . It seem interesting explore feasibility therapeutic potential association . With background , investigator perform study evaluate efficacy safety irinotecan plus raltitrexed second-line treatment advance colorectal cancer patient .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>life expectancy least 3 month ; histological and/or cytological confirmation ACC ; disease progression firstline palliative oxaliplatin &amp; fluoropyrimidine chemotherapy relapse within 6 month adjuvant oxaliplatin &amp; fluoropyrimidine chemotherapy ; washout time 4 week last chemotherapy infusion radiotherapy，and observe lesion radiotherapy target； least one measurable objective tumor lesion spiral CT examination , maximum diameter ≥ 1cm（according RECIST 1.1）； ECOG performance status 01； satisfactory main organ function，laboratory test must meet following criterion : hemoglobin ( HGB ) ≥90g/L , neutrophil count（ANC） ≥1.5×109/L , platelet count（PLT） ≥90×109/L , Serum creatinine（CR）≤1.5 upper normal limitation ( UNL ) ，creatinine clearance rate ( CCr ) ≥60ml/min , total bilirubin ( TBil ) ≤1.5 upper normal limitation ( UNL ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 UNL ( For patient liver metastasis , AST/ALT must ≤5.0 UNL ) ; For woman child bear potential , negative serum urine pregnancy test result obtain enrollment write informed consent . prior exposure irinotecan raltitrexed ; chronic enteropathy unresolved bowel obstruction ; Pregnant lactate woman ; previous malignant disease carcinoma situ cervix basal cell carcinoma skin ; Concurrent administration investigational drug , enrol clinical trial investigational drug treatment within 30 day start study treatment； cerebral metastasis leptomeningeal carcinomatosis ; severe uncompensated concomitant medical condition . Unsuitable study chemotherapy determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Raltitrexed</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Second-line Treatment</keyword>
	<keyword>Advanced Colorectal Cancer ( ACC )</keyword>
</DOC>